HRP970387A2 - Isobutylgaba and its derivatives for the treatment of pain - Google Patents

Isobutylgaba and its derivatives for the treatment of pain

Info

Publication number
HRP970387A2
HRP970387A2 HR60/022,337A HRP970387A HRP970387A2 HR P970387 A2 HRP970387 A2 HR P970387A2 HR P970387 A HRP970387 A HR P970387A HR P970387 A2 HRP970387 A2 HR P970387A2
Authority
HR
Croatia
Prior art keywords
treated
pain
animals
gabapentin
isobutylgaba
Prior art date
Application number
HR60/022,337A
Other languages
English (en)
Croatian (hr)
Inventor
Lakhbir Singh
Original Assignee
Lakhbir Singh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21809080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP970387(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lakhbir Singh filed Critical Lakhbir Singh
Publication of HRP970387A2 publication Critical patent/HRP970387A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HR60/022,337A 1996-07-24 1997-07-17 Isobutylgaba and its derivatives for the treatment of pain HRP970387A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2233796P 1996-07-24 1996-07-24

Publications (1)

Publication Number Publication Date
HRP970387A2 true HRP970387A2 (en) 1998-10-31

Family

ID=21809080

Family Applications (1)

Application Number Title Priority Date Filing Date
HR60/022,337A HRP970387A2 (en) 1996-07-24 1997-07-17 Isobutylgaba and its derivatives for the treatment of pain

Country Status (22)

Country Link
US (2) US6001876A (cg-RX-API-DMAC10.html)
EP (1) EP0934061B3 (cg-RX-API-DMAC10.html)
JP (1) JP3693258B2 (cg-RX-API-DMAC10.html)
KR (1) KR100491282B1 (cg-RX-API-DMAC10.html)
CN (1) CN1094757C (cg-RX-API-DMAC10.html)
AT (1) ATE241351T1 (cg-RX-API-DMAC10.html)
AU (1) AU714980B2 (cg-RX-API-DMAC10.html)
BR (1) BR9710536A (cg-RX-API-DMAC10.html)
CU (1) CU22850A3 (cg-RX-API-DMAC10.html)
DE (1) DE69722426T3 (cg-RX-API-DMAC10.html)
DK (1) DK0934061T6 (cg-RX-API-DMAC10.html)
ES (1) ES2200184T7 (cg-RX-API-DMAC10.html)
HR (1) HRP970387A2 (cg-RX-API-DMAC10.html)
HU (2) HU228426B1 (cg-RX-API-DMAC10.html)
IL (1) IL126999A (cg-RX-API-DMAC10.html)
NO (2) NO325822B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ332762A (cg-RX-API-DMAC10.html)
PL (1) PL189872B1 (cg-RX-API-DMAC10.html)
PT (1) PT934061E (cg-RX-API-DMAC10.html)
SI (1) SI0934061T1 (cg-RX-API-DMAC10.html)
WO (1) WO1998003167A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA976562B (cg-RX-API-DMAC10.html)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP980342A2 (en) * 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
ES2253825T3 (es) * 1997-09-08 2006-06-01 Warner-Lambert Company Llc Composiciones analgesicas que comprenden compuestos antiepilepticos y procedimientos para usar las mismas.
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
CN1303991C (zh) * 1998-05-15 2007-03-14 沃尼尔·朗伯公司 γ－氨基丁酸衍生物的稳定药物制剂和其制备方法
US20030045500A1 (en) * 1998-07-09 2003-03-06 Leslie Magnus Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
AU758103B2 (en) * 1998-07-09 2003-03-13 Warner-Lambert Company Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain
US6680343B1 (en) 1998-07-09 2004-01-20 Warner-Lambert Comapny Treatment of renal colic with GABA analogs
NZ509230A (en) * 1998-07-09 2003-08-29 Warner Lambert Co Use of GABA analogs to treat renal colic
PT1093366E (pt) * 1998-07-09 2005-02-28 Warner Lambert Co Composicao farmaceutica que contem analogos de gaba e um agente antiviral para o tratamento de herpes zoster
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
AU3735000A (en) * 1999-05-05 2000-11-21 Warner-Lambert Company Modulation of substance p by gaba analogs and methods relating thereto
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
EP1840117A1 (en) * 1999-06-10 2007-10-03 Warner-Lambert Company LLC Mono- and disubstituted 3-propyl gamma-aminobutyric acids
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
MXPA01012319A (es) * 1999-06-10 2002-07-22 Warner Lambert Co Acidos 3-propil gama aminobutiricos mono y disubstituidos.
IL152925A (en) * 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
NZ519551A (en) * 2000-01-27 2004-02-27 Warner Lambert Co Asymmetric synthesis of pregabalin
US6687187B2 (en) * 2000-08-11 2004-02-03 Phonak Ag Method for directional location and locating system
CA2356829A1 (en) * 2000-09-22 2002-03-22 Warner-Lambert Company Method for treating asthma using pregabalin
US6620829B2 (en) * 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
PT1243262E (pt) * 2001-03-20 2006-10-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica
ES2185606T3 (es) * 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ES2296956T5 (es) * 2001-06-11 2011-07-12 Xenoport, Inc. Profármacos de análogos de gaba, composiciones y sus usos.
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1412324A4 (en) * 2001-06-11 2004-09-29 Xenoport Inc AMINO ACID CONJUGATES THAT RESULT IN GABA ANALOGA LASTING SYSTEMIC CONCENTRATIONS
WO2003020273A2 (en) 2001-09-03 2003-03-13 Newron Pharmaceuticals Spa Pharmaceutical composition comprising gabapentin or an analogue thereof and an $g(a)-aminoamide and its analgesic use
AU2002316231A1 (en) 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US7183259B2 (en) * 2002-05-17 2007-02-27 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2004053192A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
AU2003297927A1 (en) * 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
AU2003283718A1 (en) * 2002-12-13 2004-07-09 Warner-Lambert Company Llc Gabapentin analogues for fibromyalgia and other related disorders
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
KR100845932B1 (ko) * 2002-12-13 2008-07-11 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 관련 질환의 치료를 위한 프레가발린및 그의 유도체
RU2353358C2 (ru) * 2002-12-13 2009-04-27 Уорнер-Ламберт Компани Ллс Производные прегабалина для лечения приливов
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20080318908A1 (en) * 2002-12-17 2008-12-25 Trustees Of Tufts College Use of gaba and gabab agonists
WO2005025675A1 (en) 2003-09-12 2005-03-24 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
CN1871021B (zh) * 2003-09-17 2010-07-28 什诺波特有限公司 用gaba类似物的前药治疗或预防多动腿综合征
PL1677767T3 (pl) 2003-10-14 2011-12-30 Xenoport Inc Krystaliczna postać analogu kwasu gamma-aminomasłowego
ATE428413T1 (de) * 2003-12-02 2009-05-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
PT1727620E (pt) * 2004-03-12 2007-11-05 Warner Lambert Co Ligandos de biofosfina c1-simétricos e a sua utilização na síntese assimétrica da pregabalina
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1735324B1 (en) * 2004-04-01 2008-08-20 Warner-Lambert Company LLC Preparation of p-chirogenic phospholanes and their use in asymetric synthesis
CN1950101B (zh) 2004-04-16 2011-03-30 舒沃茨药物股份公司 肽化合物用于预防和治疗慢性头痛的用途
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EA011765B1 (ru) 2004-06-21 2009-06-30 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си Получение прегабалина и родственных соединений
EP1781276B1 (en) * 2004-08-27 2010-06-23 UCB Pharma GmbH Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain
WO2006050514A1 (en) 2004-11-04 2006-05-11 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
CA2604602A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Method for the preparation of pregabalin and salts thereof
KR20090019016A (ko) 2005-05-10 2009-02-24 테바 파마슈티컬 인더스트리즈 리미티드 3-카르바모일메틸-5-메틸 헥산산의 광학 분할
WO2006124609A2 (en) * 2005-05-16 2006-11-23 Joseph Johnson Methods and compositions for treating arg
WO2006123247A2 (en) * 2005-05-20 2006-11-23 Pfizer Limited Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-delta-ligands
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
EP1802568A1 (en) 2005-09-19 2007-07-04 Teva Pharmaceutical Industries Ltd. Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the new synthesis of (s)-pregabalin
US7462738B2 (en) * 2006-05-24 2008-12-09 Teva Pharmaceutical Industries Ltd. Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
PT2462990E (pt) 2006-06-15 2014-04-02 Ucb Pharma Gmbh Composição farmacêutica com efeito anticonvulsivo sinergístico
KR101036536B1 (ko) * 2007-03-22 2011-05-24 테바 파마슈티컬 인더스트리즈 리미티드 (ｓ)-(+)-3-(아미노메틸)-5-메틸 헥산산의 합성
WO2009046309A2 (en) * 2007-10-03 2009-04-09 Teva Pharmaceutical Industries Ltd. Pregabalin -4-eliminate, pregabalin 5-eliminate, their use as reference marker and standard, and method to produce pregabalin containing low levels thereof
WO2009158343A1 (en) * 2008-06-23 2009-12-30 Teva Pharmaceutical Industries, Ltd. Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
WO2010070593A2 (en) 2008-12-19 2010-06-24 Pfizer Ireland Pharmaceuticals Malonate esters
WO2010099200A1 (en) 2009-02-24 2010-09-02 Nektar Therapeutics Oligomer-amino acid conjugates
NZ596492A (en) 2009-05-15 2013-08-30 Redx Pharma Ltd Redox drug derivatives
WO2010150221A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Taste masked pharmaceutical compositions of pregabalin
US20110130454A1 (en) * 2009-11-24 2011-06-02 Xenoport, Inc. Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
WO2011141923A2 (en) 2010-05-14 2011-11-17 Lupin Limited Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin
US20130078290A1 (en) 2010-06-01 2013-03-28 Rubicon Research Private Limited Gastroretentive Dosage Forms Of GABA Analogs
WO2012025861A1 (en) 2010-08-23 2012-03-01 Pfizer Manufacturing Ireland Process for the preparation of ( s ) - 3 - cyano - 5 - methylhexanoic acid derivatives adn of pregabalin
US8466297B2 (en) 2010-11-01 2013-06-18 Milan Soukup Manufacturing process for (S)-Pregabalin
WO2012059797A1 (en) 2010-11-04 2012-05-10 Lupin Limited Process for synthesis of (s) - pregabalin
WO2013114281A1 (en) 2012-01-30 2013-08-08 Ranbaxy Laboratories Limited Pregabalin gr tablets
WO2013114283A1 (en) 2012-01-30 2013-08-08 Ranbaxy Laboratories Limited Gastroretentive tablets
CN102966602B (zh) * 2012-12-14 2015-08-05 江苏海鸥冷却塔股份有限公司 一种冷却塔节能导流风筒
JP5926406B2 (ja) 2013-01-18 2016-05-25 有限会社ケムフィズ 神経因性疾病の治療のための医薬
CA2905411A1 (en) 2013-03-27 2014-10-02 Pfizer Ireland Pharmaceuticals Process and intermediates for the preparation of pregabalin
HK1253735A1 (zh) 2015-05-26 2019-06-28 艾萨‧欧蒂迪 控制延缓释放普瑞巴林
GB201617380D0 (en) 2016-10-13 2016-11-30 St George's Hospital Medical School Treatment for Osteoarthritis
KR102039345B1 (ko) 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 고팽윤성 서방성 삼중정제
KR102039344B1 (ko) 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 경구용 서방성 삼중정제
GB201703123D0 (en) 2017-02-27 2017-04-12 St George's Hospital Medical School Biomarkers
CN114621119A (zh) 2018-05-14 2022-06-14 昌郁医药公司 萘普生和普瑞巴林的1-(酰氧基)-烷基氨基甲酸酯药物缀合物的结晶形式
CN108926573A (zh) * 2018-07-03 2018-12-04 泓博元生命科技（深圳）有限公司 一种可降低尿酸指数的nadh组合物及其制备方法及应用
KR20200056719A (ko) 2018-11-15 2020-05-25 단국대학교 천안캠퍼스 산학협력단 가바펜티노이드를 포함하는, 척수손상 개체의 신경재생 또는 신경회복을 위한 조성물
WO2021150985A1 (en) 2020-01-22 2021-07-29 Seelos Therapeutics, Inc. Reducing side effects of nmda antagonists
WO2021191108A1 (en) 2020-03-23 2021-09-30 Plus Vitech, S.L. Treatment or prevention of acute organ damage induced by viral infection with a nk1 inhibitor and/or a gabapentinoid
WO2022038131A1 (en) 2020-08-19 2022-02-24 Plus Vitech, S.L. Method for the prediction of progression or prognosis of the response of a subject suffering from acute organ damage
HU231397B1 (hu) 2021-01-22 2023-06-28 Egis Gyógyszergyár Zrt. Pregabalint tartalmazó topikális gyógyszerkészítmény
CA3208954A1 (en) 2021-01-22 2022-07-28 Egis Gyogyszergyar Zrt. Topical formulation containing modified phospholipid compounds
WO2022234110A1 (en) 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy
WO2022243430A1 (en) 2021-05-20 2022-11-24 Plus Vitech, S.L. Treatment of acne
WO2022253748A1 (en) 2021-06-03 2022-12-08 Plus Vitech, S.L. Combinations for the treatment of hpv

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
JPS4940460Y2 (cg-RX-API-DMAC10.html) 1971-05-19 1974-11-06
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4123438A (en) 1975-03-05 1978-10-31 Stamicarbon, B.V. Process for preparing 2-pyrrolidones
NZ194348A (en) 1979-07-26 1982-09-14 Merrell Toraude & Co Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions
US4322440A (en) 1980-06-25 1982-03-30 New York University Anticonvulsive compositions and method of treating convulsive disorders
US4513135A (en) 1982-03-05 1985-04-23 Eli Lilly And Company Diaryl-pyrazine derivatives affecting GABA binding
DK373383A (da) 1982-08-20 1984-02-21 Midit Fremgangsmaade til fremstilling af omega-aminosyrederivater
US4479005A (en) 1982-12-16 1984-10-23 The Dow Chemical Company Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids
DE133795T1 (de) 1983-08-01 1985-09-12 The Mclean Hospital Corp., Belmont, Mass. Gaba-ester und gaba-analoge ester.
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
GB8425872D0 (en) 1984-10-12 1984-11-21 Ciba Geigy Ag Chemical compounds
NO166131C (no) 1985-06-20 1991-06-05 Daiichi Seiyaku Co Analogifremgangsmaate for fremstilling av s(-)-pyridobenzoksazinforbindelser.
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
JP2535001B2 (ja) 1987-01-13 1996-09-18 ダイセル化学工業株式会社 Ｎ−アルキル化アミノ酸エステルの製法
JPH07116064B2 (ja) 1987-07-21 1995-12-13 三菱化学株式会社 分離剤
US4908210A (en) 1988-10-28 1990-03-13 Eastman Kodak Company Lactylic salt tablet formulations and tablets
GB8911017D0 (en) 1989-05-13 1989-06-28 Ciba Geigy Ag Substituted aminoalkylphosphinic acids
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
GB8921304D0 (en) 1989-09-20 1989-11-08 Wyeth John & Brother Ltd New method of treatment and heterocyclic compounds used therein
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
AU9137091A (en) * 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
WO1992014443A1 (en) 1991-02-20 1992-09-03 Warner-Lambert Company Microsphere-in-oil emulsion
DK204791D0 (da) 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
ES2165857T3 (es) 1992-05-20 2002-04-01 Univ Northwestern Analogos de gaba y acido l-glutamico para el tratamiento de trastornos del sistema nervioso central.
GB9308430D0 (en) 1993-04-23 1993-06-09 Glaxo Group Ltd Medicaments
US5492927A (en) 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
EP0804182B1 (en) 1994-07-27 2002-06-05 Warner-Lambert Company Use of gabapentin in the treatment of anxiety and panic
US5792796A (en) 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
GB9420784D0 (en) 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
EP0802912B1 (en) 1995-01-12 2004-10-13 Glaxo Group Limited Piperidine derivatives having tachykinin antagonist activity
EA000380B1 (ru) 1995-02-28 1999-06-24 Х.Лундбекк А/С 4-аминотетрагидробензизоксазоловые или -изотиазоловые соединения, их применение и фармацевтическая композиция на их основе
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
US5616793A (en) 1995-06-02 1997-04-01 Warner-Lambert Company Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
EP0888325B1 (en) 1996-02-07 2002-05-29 Warner-Lambert Company Novel cyclic amino acids as pharmaceutical agents
IL125364A0 (en) 1996-03-14 1999-03-12 Warner Lambert Co Novel bridged cyclic amino acids and pharmaceutical compositions containing them
KR100512506B1 (ko) 1996-03-14 2005-12-21 워너-램버트 캄파니 엘엘씨 제약제제로서신규한치환시클릭아미노산
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
WO1997049393A1 (en) 1996-06-26 1997-12-31 Warner-Lambert Company Use of a tachykinin antagonist for the manufacture of a medicament for the treatment of emesis
SE9603408D0 (sv) 1996-09-18 1996-09-18 Astra Ab Medical use
HRP980342A2 (en) 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
WO1999008667A2 (en) 1997-08-19 1999-02-25 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
WO1999008670A1 (en) 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
US6127418A (en) 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
ES2253825T3 (es) 1997-09-08 2006-06-01 Warner-Lambert Company Llc Composiciones analgesicas que comprenden compuestos antiepilepticos y procedimientos para usar las mismas.
JP2002508361A (ja) 1997-12-16 2002-03-19 ワーナー−ランバート・カンパニー （（シクロ）アルキル置換）−γ−アミノ酪酸誘導体（＝ＧＡＢＡ類似体）、それらの製造および神経学的疾患の治療における使用
CN1303991C (zh) 1998-05-15 2007-03-14 沃尼尔·朗伯公司 γ－氨基丁酸衍生物的稳定药物制剂和其制备方法
CU23051A3 (es) 1998-05-15 2005-06-24 Warner Lambert Co Composiciones solidas que contienen derivados de acido gamma-aminobutirico y procesos para prepararlas.
KR20010071777A (ko) 1998-07-09 2001-07-31 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｇａｂａ 유사체 및 카페인을 포함하는 조성물
US6680343B1 (en) 1998-07-09 2004-01-20 Warner-Lambert Comapny Treatment of renal colic with GABA analogs
US20030045500A1 (en) 1998-07-09 2003-03-06 Leslie Magnus Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
CA2333024C (en) 1998-07-09 2002-03-26 Warner-Lambert Company Method for the treatment of insomnia
CA2344407C (en) 1998-10-16 2007-01-09 Warner-Lambert Company Method for the treatment of mania and bipolar disorder
AU3216600A (en) 1999-03-10 2000-09-28 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US6992109B1 (en) 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
EP1180058A1 (en) 1999-04-09 2002-02-20 Warner-Lambert Company Combinations of gaba analogs and tricyclic compounds to treat depression
JP2003525207A (ja) 1999-06-02 2003-08-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 薬剤として有用なアミノ複素環
US6642398B2 (en) 1999-06-10 2003-11-04 Warner-Lambert Company Mono-and disubstituted 3-propyl gamma-aminobutyric acids
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
ES2255500T3 (es) 1999-07-02 2006-07-01 Warner-Lambert Company Llc Combinacion simergica. gabapentina y pregabalina.
US7030119B1 (en) 1999-07-16 2006-04-18 Warner-Lambert Company Method for treating chronic pain using MEK inhibitors
JP2003512602A (ja) 1999-09-16 2003-04-02 ワーナー−ランバート・カンパニー α２δ−１サブユニット結合リガンドのスクリーニング方法
AP2002002501A0 (en) 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
NZ519551A (en) 2000-01-27 2004-02-27 Warner Lambert Co Asymmetric synthesis of pregabalin
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
WO2001088101A2 (en) 2000-05-16 2001-11-22 Warner-Lambert Company CELL LINE FOR THE EXPRESSION OF AN α2δ2 CALCIUM CHANNEL SUBUNIT
GB2365425A (en) 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
CA2356829A1 (en) 2000-09-22 2002-03-22 Warner-Lambert Company Method for treating asthma using pregabalin
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
CN1477976A (zh) 2000-11-30 2004-02-25 �Ʒ� Gaba激动剂与醛糖还原酶抑制剂的组合
PL365927A1 (en) 2000-11-30 2005-01-10 Pfizer Products Inc. Combination of gaba agonists and sorbitol dehydrogenase inhibitors
ATE291028T1 (de) 2000-12-13 2005-04-15 Warner Lambert Co P-chirale bisphospholane ligande, deren übergangsmetall-komplexe
US20040002543A1 (en) 2001-02-16 2004-01-01 Leslie Magnus Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain
ATE297902T1 (de) 2001-02-28 2005-07-15 Pfizer Prod Inc Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren
MXPA02001147A (es) 2001-03-19 2004-04-21 Warner Lambert Co Sintesis de ligandos bisfosina no-c2-simetricos como catalizadores para la hidrogenacion asimetrica.
EP1247809A3 (en) 2001-03-30 2003-12-17 Pfizer Products Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
US7022678B2 (en) 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
AU2002226634B2 (en) 2001-03-30 2007-01-25 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
TNSN03094A1 (fr) 2001-04-19 2005-12-23 Warner Lambert Co Amino-acides condenses bicycliques ou tricycliques
MXPA03009392A (es) 2001-05-25 2004-01-29 Warner Lambert Co Composicion famaceutica liquida.
US20030045449A1 (en) 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DE10203122A1 (de) 2002-01-25 2003-07-31 Gruenenthal Gmbh Verfahren zur Herstellung von substituierten Acrylsäureestern bzw. deren Einsatz zur Herstellung von substituierten gamma-Aminosäuren
EP1469841A1 (en) 2002-01-31 2004-10-27 Warner-Lambert Company Alpha 2 delta ligands to treat tinnitus
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
US20030225149A1 (en) 2002-04-30 2003-12-04 Blazecka Peter G. Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids
WO2004002462A2 (en) 2002-06-27 2004-01-08 Warner-Lambert Company Llc Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder
EP1521733B1 (en) 2002-07-08 2014-08-20 Pfizer Products Inc. Modulators of the glucocorticoid receptor
US7053122B2 (en) 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US20040092522A1 (en) 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US7071339B2 (en) 2002-08-29 2006-07-04 Warner Lambert Company Llc Process for preparing functionalized γ-butyrolactones from mucohalic acid
US7659305B2 (en) 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
CA2508601A1 (en) 2002-12-06 2004-06-24 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
KR100845932B1 (ko) 2002-12-13 2008-07-11 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 관련 질환의 치료를 위한 프레가발린및 그의 유도체
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
AU2004237951A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
JP2006526605A (ja) 2003-06-05 2006-11-24 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 治療剤としての３−置換インドール類及びそれらの誘導体
WO2005002585A1 (en) 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
GEP20084527B (en) 2003-09-03 2008-11-10 Pfizer Benzimidazolone compounds having 5-ht4 receptor agonistic activity
KR20060087560A (ko) 2003-09-12 2006-08-02 워너-램버트 캄파니 엘엘씨 알파-2-델타 리간드 및 ｓｓｒｉ 및/또는 ｓｎｒｉ를포함하는 우울증 및 불안 장애 치료용 조합물
WO2005025675A1 (en) 2003-09-12 2005-03-24 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
MXPA06003396A (es) 2003-09-25 2006-06-08 Warner Lambert Co Profarmacos de aminoacidos con afinidad por la proteina a 2d.
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
EP1543831A1 (en) 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
WO2005082372A1 (en) 2004-01-29 2005-09-09 Pfizer Products Inc. COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
GB0405200D0 (en) 2004-03-08 2004-04-21 Pfizer Ltd Combinations comprising alpha-2-delta ligands
PT1727620E (pt) 2004-03-12 2007-11-05 Warner Lambert Co Ligandos de biofosfina c1-simétricos e a sua utilização na síntese assimétrica da pregabalina
JP2007530656A (ja) 2004-03-29 2007-11-01 ファイザー株式会社 ＯＲＬ１受容体拮抗薬としてのαアリールまたはヘテロアリールメチルβピペリジノプロパンアミド化合物
EP1735324B1 (en) 2004-04-01 2008-08-20 Warner-Lambert Company LLC Preparation of p-chirogenic phospholanes and their use in asymetric synthesis
BRPI0509731A (pt) 2004-04-07 2007-09-25 Pfizer pirazol[4,3-d]pirimidinas
UA82292C2 (uk) 2004-04-14 2008-03-25 Пфайзер Продактс Инк. Спосіб стереоселективного біоперетворення аліфатичних динітрилів в ціанокарбонові кислоти (варіанти)
US20090170897A1 (en) 2004-04-20 2009-07-02 Pfizer, Inc. Method of Treating Neuropathic Pain
CN1946391A (zh) 2004-04-20 2007-04-11 辉瑞产品公司 包含α－2－δ配体的组合
WO2005102390A2 (en) 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
BRPI0510453A (pt) 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
KR100875558B1 (ko) 2004-06-15 2008-12-23 화이자 인코포레이티드 벤즈이미다졸론 카복실산 유도체
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
EA011765B1 (ru) 2004-06-21 2009-06-30 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си Получение прегабалина и родственных соединений
RU2006146675A (ru) 2004-06-29 2008-07-10 Пфайзер Продактс Инк. (Us) Способ получения производных 5-[4-(2-гидроксипропил)-3,5-диоксо-4,5-дигидро-3н-[1,2,4] триазин-2-ил] бензамида снятием защиты с промежуточных продуктов, содержащих защищенный гидроксил
US20060003344A1 (en) 2004-06-30 2006-01-05 Pfizer Inc. Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40
WO2006008640A1 (en) 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
BRPI0513717A (pt) 2004-07-23 2008-05-13 Pfizer derivados de piridina
GB0419849D0 (en) 2004-09-07 2004-10-13 Pfizer Ltd Pharmaceutical combination
ATE417830T1 (de) 2004-11-02 2009-01-15 Pfizer Sulfonylbenzimidazolderivate
CN101087771A (zh) 2004-11-10 2007-12-12 辉瑞大药厂 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物
US7122683B2 (en) 2004-11-23 2006-10-17 Pfizer Inc. Amides useful as monoamine re-uptake inhibitors
ATE460415T1 (de) 2004-11-29 2010-03-15 Warner Lambert Co Therapeutische pyrazoloä3,4-büpyridine und - indazole
ES2366375T3 (es) 2005-02-22 2011-10-19 Pfizer, Inc. Derivados de oxiindol, como agonistas del receptor 5-ht4.
WO2006092692A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
EP1858865B1 (en) 2005-03-10 2009-09-16 Pfizer Inc. Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds
EP1861359B1 (en) 2005-03-17 2012-11-14 Pfizer Inc. N-(n-sulfonylaminomethyl)cyclopropanecarboxamide derivatives useful for the treatment of pain
CA2604218A1 (en) 2005-04-20 2006-10-26 Pfizer Limited Pyrazole derivatives as progesterone receptor antagonists
JP4173909B1 (ja) 2005-04-28 2008-10-29 ファイザー・リミテッド アミノ酸誘導体
WO2006123247A2 (en) 2005-05-20 2006-11-23 Pfizer Limited Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-delta-ligands
ES2382876T3 (es) 2005-05-31 2012-06-14 Pfizer, Inc. Compuestos de ariloxi-N-biciclometil-acetamida sustituidos como antagonistas de VR1
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
NL2000284C2 (nl) 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
PL1948615T3 (pl) 2005-11-08 2012-04-30 Pfizer Ltd Pochodne pirazolu przydatne w leczeniu chorób ginekologicznych
MEP0408A (xx) 2005-12-02 2010-02-10 Pfizer Ltd Derivati hinociklicnog hinazolina kao inhibitori pde7
CA2530904C (en) 2005-12-20 2013-10-08 John Marino Pharmaceutical agents for the treatment of pain associated with spinal cord injury
EP1993529A1 (en) 2006-03-06 2008-11-26 Pfizer Products Inc. Alpha-2-delta ligands for non-restorative sleep
GB0700786D0 (en) 2007-01-15 2007-02-21 Pfizer Ltd Morpholine dopamine agonists for the treatment of pain
UA94639C2 (ru) 2007-02-02 2011-05-25 Пфайзер Продактс Інк. Трициклические соединения и их применение как модуляторов глюкокортикоидного рецептора
WO2008132589A1 (en) 2007-05-01 2008-11-06 Pfizer Limited Combinations comprising pregabalin

Also Published As

Publication number Publication date
PL331325A1 (en) 1999-07-05
IL126999A0 (en) 1999-09-22
BR9710536A (pt) 1999-08-17
NO2008018I1 (no) 2008-12-15
HK1021134A1 (en) 2000-06-02
NZ332762A (en) 2000-09-29
IL126999A (en) 2002-03-10
DE69722426T2 (de) 2004-04-08
JP3693258B2 (ja) 2005-09-07
ZA976562B (en) 1998-02-03
EP0934061A1 (en) 1999-08-11
JP2000515149A (ja) 2000-11-14
HUP9904361A2 (hu) 2000-05-28
HU228426B1 (hu) 2013-03-28
CN1223574A (zh) 1999-07-21
NO2008018I2 (no) 2010-06-28
PL189872B1 (pl) 2005-10-31
CA2255652A1 (en) 1998-01-29
SI0934061T1 (en) 2003-10-31
ES2200184T3 (es) 2004-03-01
HUS1300046I1 (hu) 2016-08-29
HUP9904361A3 (en) 2000-11-28
ES2200184T9 (es) 2015-03-20
AU714980B2 (en) 2000-01-13
AU3602497A (en) 1998-02-10
ATE241351T1 (de) 2003-06-15
NO990279L (no) 1999-01-22
CA2255652C (en) 2004-07-13
EP0934061B3 (en) 2015-01-21
USRE41920E1 (en) 2010-11-09
US6001876A (en) 1999-12-14
NO990279D0 (no) 1999-01-22
CU22850A3 (es) 2003-04-28
ES2200184T7 (es) 2015-02-10
PT934061E (pt) 2003-10-31
WO1998003167A1 (en) 1998-01-29
CN1094757C (zh) 2002-11-27
DE69722426T3 (de) 2015-05-07
NO325822B1 (no) 2008-07-21
DK0934061T3 (da) 2003-09-22
EP0934061B1 (en) 2003-05-28
DE69722426D1 (de) 2003-07-03
KR100491282B1 (ko) 2005-05-24
DK0934061T6 (en) 2015-01-26
KR20000068015A (ko) 2000-11-25

Similar Documents

Publication Publication Date Title
HRP970387A2 (en) Isobutylgaba and its derivatives for the treatment of pain
JP6076737B2 (ja) 高血圧症の防止及び治療のための組成物並びに方法
JP2016175926A (ja) 神経変性および神経炎症の治療
EP2086530A1 (en) Use of gabapentin and pregabalin prodrugs for treating tinnitus
US20090076141A1 (en) Use of Propofol Prodrugs for Treating Neuropathic Pain
US20090005444A1 (en) Use of propofol prodrugs for treating alcohol withdrawal, central pain, anxiety or pruritus
Anand et al. Sustained inhibition of brotizolam induced anterograde amnesia by norharmane and retrograde amnesia by l-glutamic acid in mice
Hilal et al. Epigenetic drugs and psychedelics as emerging therapies for alcohol use disorder: insights from preclinical studies
JP2018021023A (ja) （ｓ）２−ｎ（３−ｏ−（プロパン２−オール）−１−プロピル−４−ヒドロキシベンゼン）−３−フェニルプロピルアミドの単離された立体異性体型
EP3818981A1 (en) Synergic pharmaceutical composition of the active enantiomer (s)-ketorolac and gabapentin for the treatment of neuropathic pain
CA2255652E (en) Isobutylgaba and its derivatives for the treatment of pain
CN113181174A (zh) Bl-1249在制备治疗神经病理性疼痛的药物中的应用
JP6461961B2 (ja) ジエチル（２−シアノエチル）ホスホネートの医薬組成物および使用
HK1021134B (en) Isobutylgaba and its derivatives for the treatment of pain
Xu et al. Neuroprotectin D1 confers protection against epileptic rats by modulating neuroinflammation and autophagy
US20060004098A1 (en) Compounds useful for treating neurological disorders
JP2005513101A (ja) 慢性疼痛の治療のための２−インダニルアミノ誘導体

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODBI Application refused